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Abstract
Human immunodeficiency virus (HIV) infection results in progressive decline 
in immune function ultimately leading to acquired immunodeficiency syndrome 
(AIDS) characterised by increased susceptibility to opportunistic infections 
and malignancies. In addition, it causes immune dysfunction, which manifests 
as a persistent inflammatory state due to dysregulation of cytokine produc-
tion. Antiretroviral therapy (ART) not only improves immune function but also 
mitigates systemic immune activation associated with disease progression. Early 
initiation of ART in children living with HIV has led to a growing cohort surviving 
into adolescence and beyond. As such, they will experience lifelong exposure to an 
array of physiologic processes associated with systemic infection, immune dysfunc-
tion and antiretroviral medications. This leaves them not only susceptible to a range 
of morbidities associated with chronic inflammation, immune dysregulation, and 
drug toxicity but also vulnerable to treatment fatigue leading to issues with treat-
ment adherence and engagement in care. Children experience additional barriers to 
maintaining suppressive ART due to limited paediatric-friendly formulations that 
are palatable and contribute to regimen complexity. Tolerability and durability of 
long-term ART are integral in optimising outcomes for children and adolescents 
living with HIV and maximising viability of future ART regimens throughout 
adulthood.
Keywords: HIV, antiretroviral therapy, children, adolescents, paediatric 
formulations, adherence, HIV drug resistance, morbidity, immune dysfunction
1. Introduction
In 2018, an estimated 2.8 million children and adolescents aged between 0 
and 19 years were living with human immunodeficiency virus (HIV) globally 
[1]. There were approximately 1.6 million adolescents between the ages 10 and 
19 years, including an estimated 190,000 with newly infected HIV in 2018, major-
ity of whom reside in sub-Saharan Africa [1, 2]. Although the number of new HIV 
infections among children less than 10 years of age has declined by 41% from an 
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estimated 280,000 in 2010 to an estimated 160,000 in 2018, mostly due to success-
ful strategies for prevention of mother to child transmission (pMTCT), we are far 
from meeting the global target goals of less than 20,000 new paediatric infections 
by 2020 [1, 3].
HIV targets CD4 T cells that play an important role in both humoral and cell-
mediated immune responses to pathogens [4]. HIV infection causes immunode-
ficiency through depletion of CD4 T cells, defective function of CD4 T cells and 
macrophages, and dysregulation of cytokine production. This results in immune 
dysfunction, which manifests as increased susceptibility to opportunistic infections 
and a heightened immune activation state [5]. HIV disease progression in children 
not on ART is rapid compared to adults, and is associated with a mortality of up to 
52% by the age of 2 years in sub-Saharan Africa [6].
The Joint United Nations Programme on HIV/AIDS (UNAIDS) launched the 
90–90-90 targets in 2014 with the aim to diagnose 90% of all people with HIV, 
provide ART to 90% for those diagnosed, and attain viral suppression in 90% 
of those treated by 2020 to end the AIDS epidemic by 2030 [7, 8]. In support of 
the targets, the World Health Organisation (WHO) implemented the “treat all” 
policy in 2015 that recommends initiating anti-retroviral therapy (ART) as soon 
as practical to all people with HIV infection regardless of age or disease stage with 
the aim to improve quality of life, maximise immune preservation and potential for 
immune reconstitution, and reduce risk of transmission [9]. Despite this, only 56% 
of children under the age of 15 years were accessing treatment in 2018 with consid-
erable geographic variation in ART coverage (Table 1) [10]. Coordinated efforts to 
speed up access and availability of HIV treatment for children by stakeholders and 
development of optimal paediatric formulations still lags behind that of adults.
Early initiation of ART in children living with HIV has led to a growing cohort 
surviving into adolescence and beyond, transforming the paradigm of HIV infec-
tion from a terminal disease into a chronic condition [11, 12]. This has created 
additional management challenges related to long-term ART-associated morbidity 
and treatment fatigue. Of growing concern, despite treatment scale up, HIV mor-
tality is increasing among older adolescents (15–19 years) whilst mortality in other 
age groups is declining [13]. This reflects gaps in adolescent HIV care to address 
complex management challenges faced by this vulnerable group including lack of 
engagement in care and poor treatment adherence [13].
To achieve the global targets, HIV programs need to address management chal-
lenges in children and adolescents including scaling up access to paediatric-friendly 
Region Living with HIV
N
Receiving antiretroviral therapy
N (%)
Asia and the Pacific 110,000 87,908 (80)
Caribbean 11,000 4982 (45)
East and Southern Africa 1,100,000 679,921 (62)
Latin America 31,000 15,861 (51)
Middle east and North Africa 9900 3666 (37)
West and Central Africa 450,000 132,216 (29)
Global 1,700,000 947,243 (56)
Complete data not reported for Eastern Europe, Central Asia, Western and Central Europe, and North America.
Table 1. 
Estimates of children (0–14 years of age) living with HIV and receiving antiretroviral therapy in 2018 
(UNAIDS) [10].
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ART formulations, developing strategies to maximise engagement in care and ART 
adherence, and improve capacity to recognise and manage treatment failure to 
optimise ART durability and tolerability [8].
This chapter gives an overview of HIV-related immune dysfunction and dis-
cusses management challenges for children and adolescents living with HIV. It 
further outlines the multifaceted approaches to address these challenges to optimise 
outcomes for this vulnerable population.
2.  Immune dysfunction in children and adolescents with human 
immunodeficiency virus
HIV binds to receptors on CD4 T cells, internalises into the cell and replicates 
itself [14]. Through this process, the virus progressively destroys the infected CD4 
T cells resulting in depletion of the cells and immunodeficiency, thereby increasing 
susceptibility to opportunistic infections (Figure 1). Destruction of CD4 T cells 
can be countered by the generation of new CD4 T cells in the setting of immune 
activation, however this process may not restore all functionally important CD4 T 
cells and is not sustainable in the long-term [15]. Furthermore, HIV-related immune 
system activation and chronic inflammation has been associated with neurodevel-
opmental impairment, cardiovascular disease, and clinical HIV disease progression 
regardless of the CD4 count [16, 17].
ART arrests the HIV life cycle at various stages, thereby inhibiting replication 
of the virus. This restores cellular immunity resulting in a decline in incidence of 
opportunistic infections and improves survival. Following ART initiation, the 
incidence of the majority of opportunistic infections decreases to less than 2.5% 
[19]. ART has also been shown to reduce systemic immune activation that reduces 
inflammatory-mediated disease progression [5].
Early initiation of ART in children is critical for immune reconstitution and 
long-term immune preservation. Mathematical modelling using data from large 
Figure 1. 
Association between opportunistic infections and CD4 count [18]. CMV: Cytomegalovirus; MAC: 
Mycobacterium avium complex; PJP: Pneumocystis jirovecii pneumonia; PML: Progressive multifocal 
leukoencephalopathy.
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European and African cohorts indicate that both age and CD4 count at ART initia-
tion are important determinants of CD4 cell recovery [20, 21]. Children initiating 
ART under the age of 5 years have better potential for CD4 count recovery, with the 
potential for long-term CD4 count recovery diminishing every year after the age of 
5 years that ART is initiated.
3. Antiretroviral therapy challenges in children and adolescents
There are limitations to paediatric-friendly ART formulations that pose impor-
tant obstacles to maintaining good adherence in children. Most available paediatric 
ART formulations have poor palatability and constitute complex regimens [9]. 
Children often have to take a combination of pills and liquid formulations with 
short dosing intervals making it challenging for caregivers to administer. Fixed dose 
combinations (FDCs), which combine two or three antiretroviral medications have 
been shown to improve adherence [9]. Nonetheless, there are few available FDCs 
in non-pill form, limiting administration to older children who can swallow large 
pills. Complex storage and transportation is another challenge particularly with the 
liquid formulations that require cold chain storage [9].
ART drug development for children still lags behind that of adults despite major 
achievements in improving access to ART worldwide. There are a number of barri-
ers slowing drug development for children. These include, lack of economic incen-
tives for manufacturers contributed by the small paediatric market, with children 
making up less than 10% of people living with HIV and declining numbers of new 
paediatric HIV infections. The technical and pharmacokinetic complexities related 
to development of formulations that are safe, palatable and allow dosing across 
various ages and weight is challenging, requiring extensive research. Furthermore, 
outdated procurement practices and gaps in supply chains, delay in regulatory 
approvals at an individual country level, and stagnant government policies can 
result in further delay in uptake of new ART into treatment programs [11, 12].
The WHO ART recommendations for children are evolving with development 
of new antiretroviral medications. Most recently in 2018, WHO updated its treat-
ment guidelines and now recommends the new integrase strand transfer inhibitor 
(INSTI)-based ART regimens including dolutegravir (DTG) for children older than 
4 weeks of age and raltegravir (RAL) for neonates as a first line option (Table 2) 
[3]. INSTIs are comparatively efficacious, have a high barrier to resistance, and are 
better tolerated than protease inhibitors (PIs). However, the use of DTG is restricted 
by the only available DTG formulation (50 mg tablet) being approved for use in 
children who are at least 20 kg, with DTG dosing guidance for children less than 
Preferred Alternative Special circumstances***
Neonates AZT + 3TC + RAL AZT + 3TC + NVP AZT + 3TC + LPV/r
Children ABC + 3TC + DTG* ABC + 3TC + LPV/r
ABC + 3TC + RAL
ABC + 3TC + EFV**
AZT + 3TC + EFV**
AZT + 3TC + LPV/r
AZT + 3TC + NVP
AZT + 3TC + RAL
ABC + 3TC + RAL
*DTG approved in children > = 20 kg.
**From 3 years of age.
***Where no alternatives are available.
Table 2. 
WHO 2018 recommendations for first line paediatric antiretroviral regimens [23].
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20 kg still under development [3]. This along with the limited manufacturing capac-
ity and cost limit accessibility of these regimens limit the use of INSTIs in children.
In the interim, lopinavir/ritonavir (LPV/r)-based regimens remain the only 
available first line ART for infants and young children as recommended by 
WHO. They are superior and more effective than the non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) such as nevirapine (NVP) and efavirenz (EFV) 
[11]. There is also comparatively high resistance to NNRTIs, particularly in children 
whose mothers received NNRTIs to prevent mother to child transmission, which 
further limits the use of this drug class as first line [22]. Table 2 illustrates the WHO 
recommended first line paediatric ART regimens for neonates and children.
LPV/r is available as an oral solution, heat stable tablets, oral pellets and oral 
granules. The LPV/r liquid formulation was developed for ease of administration 
in younger children and infants. However, the liquid formulations have issues with 
palatability and require caregivers to measure out the precise amount of liquid. 
Additionally, liquid formulations need cold chain storage, which can be an obstacle 
in resource limited settings [9]. In 2015, the USA food and drug formulation tenta-
tively approved LPV/r oral pellets, and subsequently approved LPV/r oral granules 
in August 2018 [24]. The pellet and granule formulations offer advantages over the 
liquid form as they are easy to administer across dosing ranges, easy to store and 
transport, and palatable. However, there has been a slow uptake of these formula-
tions in low and middle-income countries due to limited manufacturing capacity, 
making policy makers reluctant to transition to LPV/r based ART regimens [24].
Alternative PIs such as darunavir/ritonavir (DRV/r) may be an option for chil-
dren above 3 years of age who have failed first line LPV/r-based treatment. Studies 
have shown darunavir is not only effective in ART paediatric-experienced patients 
but also has low rates of resistance among children with prolonged PI exposure [25]. 
However, DRV/r is not recommended for children under the age of 3 years due to its 
toxicity profile. Although DRV/r is available as an oral solution, there is a paucity of 
data regarding its tolerability in young children.
With evolving optimal, new antiretroviral treatment options, children continue 
to be exposed to several classes of ART throughout their lives. Appropriate sequenc-
ing of age- and weight-based ART regimens, along with long-term treatment-
related morbidities remains unclear and needs ongoing evaluation.
The innovations for paediatric-friendly formulations should strive towards 
safe, effective and palatable ART for children [9]. Several strategies have been put 
in place to improve development and access to paediatric-friendly formulations 
including:
• The Global Accelerator for Paediatric Formulations (GAP-f), a new mecha-
nism working to support and formalise collaboration across sectors, and 
accelerate both upstream (strict drug regulatory authority filing and approv-
als, formulation development by innovators and generics, and generic manu-
facturing) and downstream processes (national treatment policy, management 
of supply chains and market uptake) to ensure that children are able to access 
the new optimal paediatric antiretroviral medications [26].
• Improving incentives for paediatric formulation development. Pharmaceutical 
companies Cipla and Mylan that developed LPV/r pellets and granules respec-
tively, have committed to increase supply to meet the growing demand of these 
formulations until DTG generic formulation and dosing for children less than 
20 kg becomes available. It will be essential for the Antiretroviral Procurement-
Working Group (APWG) to regularly keep track of demands to ensure supply 
is not stripped [3].
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• Investment in development of palatable, safe and effective antiretroviral medi-
cations and simplified regimens for ease of administration. FDC, ideally once 
a day, formulations would be beneficial in particular LPV/r-based regimens for 
children who cannot swallow tablets and potentially serve as an alternative for 
children who do not tolerate DTG (Table 3) [3]. Development of a FDC in the 
pipeline is ABC/3TC/DTG, a WHO recommended regimen, in a single formu-
lation which will simplify treatment. However, there remains uncertainty as 
to the timing of its availability on the market and dosing guidance for children 
under 20 kg [3].
• Accelerating availability of DTG dosing for infants and young children through 
provision of incentives. Recently Unitaid provided financial incentives to the 
pharmaceutical companies Mylan and Macleods working to develop a generic 
DTG 10 mg dispersible tablet, which would be suitable for children <20 kg [3]. 
ViiV also committed to filing their 5 mg dispersible DTG with the US Food and 
Drug Administration (FDA) (Table 3).
• National programs should rapidly take up new formulations as they become 
available and timely provide necessary training to health care workers respon-
sible for prescribing these medications.
Although there has been some progress with development of paediatric-friendly 
formulations discussed above, accelerating these processes remains a priority in 
order to achieve treatment success. Ongoing research and regular surveillance 
on access and uptake of the new ART formulations at national and global level is 
vital to recognise and address challenges that may arise. Additionally, longitudinal 
studies are needed to examine the long-term effects of exposure to several classes of 
ART in the paediatric population and optimal sequencing strategies of ART to limit 
treatment failure.
3.1 Non-adherence to antiretroviral treatment among children and adolescents
ART leads to improved survival and reduced HIV transmission rates, however 
high levels of adherence are required for sustained effects. Adherence to antiretro-
viral therapy is critical to achieve virological suppression, immune reconstitution 
and ultimately improved clinical outcomes among children and adolescents living 
with HIV [27]. Sub-optimal adherence includes missed doses, treatment interrup-
tions or discontinuation, and sub-therapeutic dosing [28]. Non-adherence to ART 
is not only a barrier to achieve treatment success but is also a driver of resistance 
limiting future treatment options, and potentially increasing the risk of secondary 
transmission of drug resistant virus.
Adherence is a complex, dynamic process that can vary throughout the course 
of treatment and needs to be assessed continuously [29]. Adherence behaviour is 
influenced by multiple factors that can interplay with each other at different stages. 
These include patient factors, family and carer factors, patient-provider relation-
ship, socio-cultural and medication related factors [28, 29]. It is therefore important 
to work closely with family, caregivers, and children and adolescents to best under-
stand the barriers to adherence specific to the individual in order to provide tailored 
support.
Assessment of adherence should be routine with every clinic visit. A system-
atic review on ART adherence in adolescents with HIV found almost 40% are 
non-adherent to treatment [30]. In resource-limited settings, the range of ART 
adherence has been reported from 49–100% [29]. A contributing factor to this wide 
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variation is the lack of standardised methods for measuring adherence. In most 
instances, adherence is measured subjectively by self or caregiver reporting, and 
hence is subject to self-enhancement and recall bias. Objective measures of adher-
ence are costly and include HIV viral load, pill counting, electronic dose monitoring 
and drug detection in biological samples [13, 28, 29]. Discrepancies between pill 
count and viral load results of 40% have been reported [29].
3.1.1 Barriers to antiretroviral therapy among adolescents living with HIV
Adolescence is a period of dramatic neurocognitive and physiological change 
and often includes experimentation with sexual behaviour, alcohol and recreational 
drug use. Furthermore, there is a decrease in the engagement of health care services 
that may influence adherence [12, 30]. The rising mortality for older adolescents 
(15–19 years) living with HIV has been attributed to complex challenges with ART 
adherence and poor retention in care [30].
Several factors contribute to adherence behaviour in this age group. These 
include [27]:
• Lifestyle barriers such as forgetting to take medications, worrying about 
disclosure of HIV status, and varied schedules (e.g., schooling)
• Physical factors such as feeling well that may result in complacency and 
neglecting to take antiretroviral medications.
• Medication related barriers including: (i) treatment fatigue, an important fac-
tor particularly in adolescents with perinatal HIV infection who have experi-
enced multiple ART regimens over a prolonged period; (ii) complexity of ART 
regimens (e.g., pill burden and frequent dosing); (iii) toxicities and adverse 
effects associated with ART that lead to a reluctance in taking medications.
• Lack of health literacy, poor treatment knowledge and/or understanding of the 
importance of treatment adherence.
Formulation Q3
2019
Q4
2019
Q1
2020
Q2
2020
Q3
2020
Q4
2020
LPV/r Cipla pellet 
and Mylan 
granule 
capacity 
expansion
ABC/3TC/
LPV/r
Cipla FDA 
filing
Mylan FDA 
filing
Cipla FDA 
approved 
(t)
Mylan 
FDA 
approved 
(t)
DTG ViiV 
DTG 
5 mg 
DT FDA 
filing
Mylan and 
Macleods 
DTG 10 mg 
DT scored 
FDA filing
ViiV DTG 
5 mg 
DT FDA 
approval
Mylan and 
Macleods 
DTG 10 mg 
scored 
DT FDA 
approval (t)
3TC: Lamivudine; ABC: Abacavir; DT: Dispersible tablet; FDA: Food drug administration; LPV: Lopinavir; Q: 
Quarter; r: Ritonavir; (t): tentative.
Table 3. 
Estimated timeline for development of key paediatric antiretroviral therapies [3].
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• Disclosure status, including non-disclosure of HIV status to adolescents with 
perinatal HIV infection by caregivers.
• Structural factors such as lack of transport to travel to the clinics to obtain 
medications [27].
3.1.2 Barriers to antiretroviral therapy among children with HIV
The obstacles to adherence in children include limited paediatric-friendly 
formulations (as previously discussed), barriers associated with caregivers that 
includes forgetting doses, incorrectly measuring liquid formulations, and changes 
in routine resulting in delays in administration. Some caregivers place responsibil-
ity for managing medications to older children before they are developmentally 
prepared to undertake such a task. Socio-cultural factors that influence adherence 
across the age groups include poverty, violence, substance abuse, poor mental 
health and lack of social supports.
3.1.3  Interventions to improve adherence to antiretroviral therapy in children and 
adolescents
Interventions to improve adherence should be tailored to the individual’s needs.
Strategies to improve adherence can be grouped as medication-related, patient/
family-related, and health care provider-related strategies.
3.1.3.1 Medication-related strategies
• Efforts should be made to simplify regimens with regards to the number 
of pills or volume of liquid required to be administered and reduce dosing 
frequency. When feasible, once daily FDC antiretroviral regimens should be 
prescribed to lessen pill burden and hence improve adherence particularly for 
older children and adolescents [28].
• Pill swallowing training [28, 31].
• Adherence support through medication education, blister packs and refill 
reminders.
• Wider access to paediatric-friendly formulations that are palatable.
• Minimising drug toxicities through regular monitoring for adverse effects and 
potential drug–drug interactions, and a proactive approach in trialling differ-
ent dosing strategies or switches in ART regimens as required (if feasible).
3.1.3.2 Patient/family-related strategies
Health care providers should evaluate potential barriers to adherence, discuss 
goals of therapy, importance of optimising adherence, and strategies to support 
adherence prior initiating ART [28]. Demonstration of drug administration equip-
ment such as use of syringes and medication cups, and ensuring supply of these is 
important. Provision of information and adherence tools such as written and visual 
aids may be useful, however this should take into consideration literacy levels of the 
caregiver.
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The use of behaviour modification techniques such as positive reinforcements 
and provision of incentives to encourage medication compliance can be effective. 
Trained community outreach workers can provide directly observed therapy and 
closer adherence support to children with poor adherence particularly those living 
in regional or remote settings [28]. This can be resource intensive, and therefore 
not a sustainable long-term solution in low- and middle-income countries. Early 
recognition and treatment of mental health disorders such as depression, which 
may impact adherence, should be addressed. This will depend on availability of 
appropriate mental health services.
In instances where the child has not been informed of their HIV status, timing of 
HIV disclosure should be discussed with the caregivers. A systematic review evalu-
ating ART adherence and disclosure demonstrated mixed results, with some studies 
showing improved adherence while other studies finding worse adherence [28, 32]. 
The decision to disclose HIV status should take into consideration the needs of the 
child and family, cognitive capacity of the child and psychosocial situation.
For adolescents living with HIV, it is paramount to engage them in management 
decisions. Use of electronic devices to support adherence such as mobile applica-
tions that serve as reminders to take medications and sending text message remind-
ers may be useful. A systematic review found the two most effective interventions 
were a phone-based counselling approach with adherence monitors and weekly 
individual and family counselling [13].
3.1.3.3 Health care provider related strategies
Health care providers can improve adherence by establishing a rapport with 
the patient and family, fostering a trusting relationship and encouraging open 
communication.
Creating child and adolescent centred multidisciplinary health care settings has 
been shown to improve treatment outcomes. Adolescent-friendly clinics providing 
peer counselling, peer navigators and psychosocial supports at clinics and school 
have demonstrated substantial improvement in retention of adolescents and young 
adults living with HIV [13]. Such a service also presents a supportive environment 
to discuss adherence barriers, provide reproductive health education, mental health 
and disclosure supports, and social activities to promote not only adherence but 
also retention.
Factors that influence adherence are complex and dynamic, and need to be 
continuously assessed [29]. A multidisciplinary approach to address adherence 
challenges is necessary. There remains a paucity of evidence supporting interven-
tions that improve adherence particularly in adolescents. As such, there is a need for 
evidence-based innovative interventions that are feasible, sustainable and impor-
tantly tailored to the individual patient. Ultimately, this will improve treatment 
outcomes, reduce resistance to ART and be an important step forward towards 
achieving global targets [13].
3.2 Antiretroviral treatment-related morbidity
The benefits of early initiation and improved access to ART are well recog-
nised, resulting in significant reduction in HIV related morbidity and mortality. 
Nonetheless, children and adolescents with early exposure to ART experience an 
array of multisystem morbidities including metabolic complications, increased risk 
of cardiovascular disease, and neuropsychological challenges. In this section, we 
discuss morbidities associated with ART faced by children and adolescents.
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3.2.1 Metabolic complications
Lipodystrophy syndrome involves redistribution of body fat, which can 
manifest as lipoatrophy (decrease subcutaneous fat in the face and limbs) with or 
without central adiposity (lipohypertrophy) [33]. The prevalence of lipodystrophy 
among children living with HIV can range from 1–57% [34–36]. Studies from 
sub-Saharan Africa reported a lipodystrophy prevalence of 27–30% among children 
aged 1 to 18 years, with older children and use of stavudine (d4T) being major risk 
factors [33].
The pathogenesis of ART-related lipodystrophy is not well understood and felt 
to be multifactorial including direct effects on lipid metabolism, mitochondrial 
toxicity and genetic predisposition. Lipodystrophy is a complication of the NRTIs 
including d4T and zidovudine (AZT). PIs have also been implicated but to a lesser 
extent. Lipodystrophy has been described to most likely develop during puberty, 
and such body changes can result in stigmatisation potentially leading to poor 
adherence and treatment failure.
The diagnosis of lipodystrophy is usually clinical, particularly in resource-lim-
ited settings. Anthropometric measurements may be used, which are inexpensive 
but require experience and standardisation. The use of dual energy X-ray absorp-
tiometry to assess fat distribution is restricted by cost in resource-limited settings 
[33]. Active clinical surveillance for fat maldistribution particularly in children 
receiving antiretroviral drugs associated with lipodystrophy and monitoring of 
lipid profile is necessary.
Insulin resistance and dyslipidemias are commonly linked to lipodystrophy, 
potentially increasing the lifetime risk of cardiovascular disease. PIs have been 
associated with elevated triglycerides, low-density lipoprotein cholesterol and total 
cholesterol. Children receiving LPV/r have been shown to have higher low-density 
lipoprotein cholesterol and triglyceride levels compared to children receiving NVP 
[37]. Although the long-term risk of cardiovascular disease in children on ART 
remains uncertain, the observed elevation in cholesterol levels at a young age is 
a predictor of long-term risk of premature atherosclerotic disease. Lipid profiles 
should be obtained from children and adolescents prior initiation of ART and 
 ideally monitored every 6–12 months.
Insulin resistance is less common in children compared to adults. Impaired glu-
cose homeostasis has been reported in 8–35% of children with HIV on ART, which 
includes impaired glucose tolerance, impaired fasting glucose and type 2 diabetes 
mellitus [33]. Prolonged exposure to high insulin levels may increase the risk of 
type 2 diabetes mellitus, a risk factor for cardiovascular disease. Management of 
insulin resistance includes lifestyle modifications (e.g., diet and exercise), as well as 
 switching to a PI-sparing regimen.
3.2.2 Cardiovascular disease
Cardiovascular complications of HIV infection was recognised early in the 
epidemic particularly in adults. Evidence suggests children and adolescents with 
perinatal HIV infection may be at risk of cardiovascular disease due to long term 
viral effects and exposure to certain classes of ART, especially NRTIs and PIs [33].
Potential cardiovascular risk factors for children with perinatal HIV Infection 
include dyslipidaemia associated with PIs, as well as heightened vascular inflam-
mation and endothelial dysfunction that may predispose to future atherosclerosis, 
however supporting data remains limited [33]. HIV related cardiomyopathy has 
been reported as a potential cardiovascular complication, with a suggested patho-
genesis involving mitochondrial toxicity associated with NRTIs (e.g., zalcitabine, 
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didanosine (ddI), d4T and AZT), viral cytopathic effects on cardiac myocytes, and 
increased cytokine production within the myocardium [38].
Children with perinatal HIV infection remain at risk of long-term cardiovas-
cular disease and thus warrant close surveillance [38]. This may be a challenge in 
resource-limited settings where diagnostic screening for cardiovascular disease may 
not be readily available. Therefore, an emphasis should be placed on prevention 
strategies such as lifestyle modifications, whilst more cost-effective cardiovascular 
monitoring needs to be evaluated [33].
3.2.3 Lactic acidosis
Hyperlactatemia is a well-known complication of ART. It can vary in severity 
from asymptomatic to life threatening. In children, the estimated prevalence of 
mild to moderate hyperlactatemia is 35–50%, with severe forms being rare [33].
Lactic acidosis has been associated with NRTI-induced mitochondrial toxicity. 
D4T and ddI have the greatest effect, with AZT, 3TC, tenofovir disoproxil fuma-
rate (TDF) and abacavir (ABC) having a lesser effect on the mitochondria. Most 
children with hyperlactatemia are asymptomatic [33]. The clinical presentation of 
lactic acidosis is non-specific and can include malaise, abdominal pain, vomiting, 
muscle weakness and dyspnoea. Supportive laboratory findings include elevated 
transaminases, lactate dehydrogenase deficiency, amylase, lipase, increased anion 
gap on venous blood gas and a raised lactate level. Diagnosis requires a high index of 
clinical suspicion and confirmed with raised venous lactate level [33].
Management of lactic acidosis involves ceasing the offending antiretroviral 
agent and switching to an agent that is less likely to cause mitochondrial toxicity. 
In severe forms, NRTI–sparing regimens are advisable [33].
3.2.4 Bone disease
Children and adolescents with perinatal HIV infection are considered at 
increased risk for lower bone mineral density (BMD) due to the effects of a 
chronic viral infection and exposure to ART (particularly TDF), though the evi-
dence is mixed [38]. Some studies illustrate significant BMD loss among children 
treated with TDF-containing salvage regimens [39, 40], whilst other studies 
demonstrate no association [38]. Other risk factors associated with low BMD 
include advanced HIV stage and a high viral load [33]. Furthermore, HIV infec-
tion is an established cause of pubertal delay which may influence bone mass and 
subsequent risk of osteoporosis and fractures. Long-term use of certain contracep-
tives such as depot medroxyprogesterone acetate may contribute to loss of BMD in 
adolescent females [41].
Longitudinal data are required to further evaluate bone density changes through 
puberty while on ART to guide treatment regimens and identify bone disease 
among children and adolescents with perinatal HIV infection [38]. In addition, 
further exploration to identify interventions to minimise the long-term risk of 
osteoporosis are needed.
3.2.5 Psychological complications
Children and adolescents with perinatal HIV infection are at increased risk of 
mental and behavioural disorders. This is influenced by several factors including 
long-term chronic disease management, psychosocial stressors, stigma and the 
neurocognitive impact of HIV infection. The most common mental health disorders 
reported include anxiety, depression, behavioural disorders, learning difficulties 
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and attention deficit hyperactivity disorder [38]. HIV health care providers should 
be trained to integrate screening of mental health and behavioural disorders into 
routine care of these children and refer to appropriate services where available. This 
is an integral component of the holistic long-term management of HIV that will 
ultimately serve to improve ART adherence, engagement in care, neurocognitive 
development and social relationships [41].
3.2.6 Reproductive health complications
Clinicians managing adolescents of childbearing potential should assess their 
fertility intentions and review the potential drug–drug interactions between ART 
and contraception options to avoid adverse outcomes. There are potential interac-
tions between NRTIs and some PIs with oral contraceptives that reduces their 
efficacy; whereas RAL does not interact with oestrogen-based contraceptives. There 
is preliminary data to suggest DTG may increase the risk of neural tube defects [41], 
and this should be a consideration when discussing ART regimen options during 
pregnancy. As part of comprehensive HIV care, reproductive health education 
should be provided to adolescents including risks of sexual transmission of HIV 
(and other infections) and perinatal HIV transmission, contraception, and access to 
family planning services.
3.3 Resistance to antiretroviral therapy
Development of HIV drug resistance resulting in treatment failure is a growing 
concern. Resistance to ART limits alternative treatment options, fuels progression 
of HIV disease and threatens the success of treatment programs [42]. There are 
three classes of HIV drug resistance. Acquired drug resistance (ADR) develops 
when HIV mutations emerge while on antiretroviral medications. Transmitted drug 
resistance (TDR) occurs through the transmission of resistant HIV. Pre-treatment 
drug resistance (PDR) is detected in anti-retroviral naïve patients as a result of 
TDR or following exposure to ART through pMTCT strategies [42]. PDR is a strong 
predictor of treatment failure and should inform recommended first line ART 
regimens. The WHO advises a national PDR prevalence of greater than 10% to an 
antiretroviral drug or drug class as an indication to switch to a different empiric 
first line ART regimen [42].
Studies across sub-Saharan Africa have shown virological failure ranging 
between 13 and 64% [43–47], with the proportion of antiretroviral drug resistance 
around 90% among those with virological failure [45, 46]. National surveys on HIV 
drug resistance in newly diagnosed HIV infection in infants and children less than 
18 months of age across sub-Saharan African countries found an overall prevalence 
of HIV drug resistance to one or more antiretroviral drugs of 54.1% [22]. NNRTI 
resistance was present in 53%, predominantly in pMTCT-exposed children; and 
NRTI resistance present in 8.9%, which was largely driven by d4T and lamivudine 
(3TC)/emtricitabine (FTC) resistance reflecting the d4T/3TC backbone used at the 
time in these countries. A systematic literature review on PDR from 13 sub-Saharan 
African countries found a PDR prevalence of 42.7% in pMTCT-exposed children 
compared to 12.7% in pMTCT-unexposed children [48]. This study also demon-
strated an increase in PDR in pMTCT–unexposed children from 0% in 2004 to 
26.8% in 2013, which likely reflects NNRTI TDR from pregnant and/or breastfeed-
ing women to their children. These findings are supported by a systematic literature 
review on PDR in children starting ART in low-and middle-income countries, 
which found a median prevalence of NNRTI resistance of 49.3% and more than 
50% of pMTCT-exposed children with NNRTI resistance [49].
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The high prevalence of PDR to NNRTIs in children supports recommendations 
to commence children on PI- or DTG-based regimens as the preferred first line 
due to lower levels of PDR and higher barriers to resistance. Longitudinal observa-
tional data from an Asian cohort of children and adolescents receiving second line 
PI-based regimens showed acquired PI resistance of less than 10% [50]. PI PDR 
prevalence rates in infants and young children in sub-Saharan African countries are 
reported as less than 3% [42]. This is likely due to the low rate of maternal PI-based 
regimens and the higher barrier to resistance for boosted PI regimens. However, 
widespread use of PI-based regimens in resource-limited settings has been hindered 
by the lack of access to appropriate paediatric-friendly formulations, prohibitive 
costs and procurement issues [42].
It is paramount to sustain high levels of viral suppression among children and 
adolescents with HIV in order to minimise development of HIV drug resistance 
[42]. To help achieve this, scaling up of viral load monitoring and HIV genotyping 
at initiation of treatment and throughout treatment is necessary to better under-
stand the prevalence of antiretroviral drug resistance in children and adolescents. 
This will allow early recognition of treatment failure and guide treatment adjust-
ments to subsequent suppressive ART regimens. Continued efforts to improve 
treatment adherence, prioritising first line therapies with high genetic barriers to 
resistance and ensuring availability of third line therapy is critical to reaching the 
UNAIDS 90-90-90 target goals [46].
4. Conclusion
Successful efforts of pMTCT programs has resulted in declining numbers of 
HIV infection in children worldwide. However, a considerable number of children 
and adolescents are living with HIV who require lifelong ART. HIV causes progres-
sive CD4 T cell-related immunodeficiency and chronic immune system activation 
that results in an array of infectious and non-infectious morbidities and mortality. 
Early ART initiation is integral in achieving the treatment goals of maximising 
sustained viral suppression, optimising immunologic status, reducing HIV-related 
morbidity, and increasing survival. The global scale-up of ART has transformed 
HIV into a manageable chronic disease, however children and adolescents living 
with HIV continue to face unique management challenges with respect to ART and 
supportive care.
ART adherence and engagement in care are key to achieving the goals of therapy. 
Current challenges to ART adherence include the limited availability of paediatric-
friendly formulations, lack of simplified regimens, and psychosocial complexities 
of managing children and adolescents through periods of marked biopsychosocial 
development. To improve ART adherence in children there is a need to acceler-
ate development of paediatric-friendly formulations that are palatable and safe 
for children, with simplified regimens that are easy to administer and able to be 
transported and stored with minimal resources. Investment and collaboration 
across public and private sectors are integral to promote access to such paediatric-
friendly ART globally. A holistic, multidisciplinary approach to managing children 
and adolescents living with HIV through the provision of comprehensive child and 
adolescent HIV health services that provide psychosocial support, surveillance and 
management of disease- and treatment-related morbidity, mental health screen-
ing, and reproductive health counselling is necessary to optimise engagement in 
care and treatment outcomes. Ongoing efforts to implement effective strategies to 
identify and manage treatment failure, through upscaling of HIV viral load testing, 
enhanced adherence support, and access to alternate effective ART regimens are 
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required to maximise ART durability, minimise the development of antiretroviral 
resistance, and preserve future ART options.
Children and adolescents living with HIV have been and will continue to be 
exposed to various ART regimens throughout their lives as new antiretroviral 
agents become available and novel ART regimens introduced. The long-term impact 
of lifelong exposure to multiple antiretroviral agents with regards to treatment 
response and morbidity is uncertain and needs ongoing evaluation. Longitudinal 
studies are essential to provide data on long-term treatment outcomes and antiret-
roviral drug toxicities to inform optimal sequencing of ART regimens.
A coordinated approach incorporating all stakeholders involved in addressing 
HIV in children and adolescents throughout their life course is necessary to navigate 
the challenges in reaching the successive targets set for children and adolescents in 
overcoming the epidemic. This will require sustained financial, research, and politi-
cal commitment to best inform HIV models of care for this vulnerable group.
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